A Study to Assess the Bioavailability and to Compare the Pharmacokinetics of AZD7594 Inhaled Via Monodose Inhaler and Multiple-dose Dry Powder Inhalers (DPI) or Pressurized Metered-dose Inhaler (pMDI) in Healthy Male Subjects

Conditions

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)

Interventions

• DRUG: AZD7594 Solution for infusion (150 μg intravenous formulation)
• DRUG: AZD7594 Oral suspension (1200 μg oral formulation)
• DRUG: AZD7594 Inhalation powder (400 μg) by DPI Device 1 (monodose inhaler)
• DRUG: AZD7594 Inhalation powder (400 μg) by DPI device 2 (multiple-dose inhaler)
• DRUG: AZD7594 Pressurized inhalation suspension (400 μg) by pMDI

Sponsor

AstraZeneca